profile_id,first_name,last_name,sub_title,profile_picture,background_image,profile_type,entity_urn,object_urn,birth_date,summary,location,premium,influencer,treasury_media,languages,industry,education,patents,awards,certifications,organizations,projects,publications,courses,test_scores,position_groups,volunteer_experiences,skills,network_info,related_profiles,contact_info
goranmedic,Goran,"Medic, PhD, Pharm.D.",Director HEOR at Philips,https://media.licdn.com/dms/image/D4E03AQG-aDG2wFggGQ/profile-displayphoto-shrink_800_800/0/1684426628548?e=1697673600&v=beta&t=1ZUVmTovRaPeYDbqb7BNyji8XKweB1oZI06ztEXR9gA,,personal,ACoAAAC9cSwB9ZiyAklLzLANffUPhGUQQBypKSo,12415276,,"As a director-level expert, Goran has over 19 years of comprehensive experience in health economics, outcomes research, and reimbursement across pharmaceutical, medical device, and consulting sectors. With in-depth knowledge of European and US healthcare systems, he is driven to develop HTA value propositions and data-driven solutions, enabling access to innovative treatments for patients.

Goran's expertise covers digital health, medical devices, and diverse disease areas, including rare diseases, oncology, cardiovascular, rheumatoid arthritis, infectious diseases, and psychiatric disorders.

A proven leader, Goran excels in managing and influencing individuals beyond his direct reports, delivering results in complex, matrix environments, and addressing challenges involving multiple stakeholders.

His specialties include:
* Health economics - Developing customer-focused economic models based on real-world data (budget impacts, outcomes analyzers, pricing, etc.);
* Digital health and medical devices;
* Communication tools and content creation (economic value presentations, value messages, abstracts/manuscripts, posters, payer slide kits, etc.);
* Reimbursement of orphan drugs in Europe;
* Pricing questionnaires;
* Medical writing;
* Submission dossiers;
* Pharmacist.","{'country': 'Netherlands', 'short': 'The Randstad, Netherlands', 'city': 'The Randstad', 'state': 'Netherlands', 'default': 'The Randstad, Netherlands'}",False,False,"[{'url': None, 'title': 'Costs of Ventilation Options Derived from nThrive Database – Retrospective Database Analysis', 'description': None, 'image': 'https://media.licdn.com/dms/image/C562DAQECSWVQAnPvfA/profile-treasury-document-cover-images_1920/0/1609249590839?e=1692892800&v=beta&t=1__PBmZXFGPoL2JKYU8rjECGAssHkmMUkGcLlUy8kj4'}, {'url': None, 'title': 'Use of surveillance data to examine the cost-effectiveness of alternative approaches to empiric antibiotic therapy in Gram-negative nosocomial pneumonia', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQGNqTsLFfBC7w/profile-treasury-document-cover-images_1920/0/1584081358403?e=1692892800&v=beta&t=cS3FfI0FgFJYaSbLPVQeDjcpYXfJGRKBZ5aPs3leRlU'}, {'url': None, 'title': 'Rx to OTC switch - Is this the next big thing?', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQFXOjVHiPNphA/profile-treasury-document-cover-images_1920/0/1583609871300?e=1692892800&v=beta&t=-ytzbL-zd9KpN1g45HFkkBB7pwjZoI64cCSZ8lXhh1U'}, {'url': None, 'title': 'Impact of PE modelling on reimbursement of medicines in Serbia', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQEWf2sZ7s1bLg/profile-treasury-document-cover-images_1920/0/1583899719691?e=1692892800&v=beta&t=nb_KbhbL5k0GpUOk7Jqb9Pob_9D7ZHunYCHQaq1OatU'}, {'url': None, 'title': 'Clinical trials and network meta-analysis: side by side', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQGMBNbI4k8Aig/profile-treasury-document-cover-images_1920/0/1583895726679?e=1692892800&v=beta&t=ORa4Hil-rOsxLCMlVHU_swsFCCojraervUln98slkvc'}, {'url': None, 'title': 'Relative efficacy of bivalirudin vs. heparin monotherapy in patients with STEMI treated with primary PCI: a NMA', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQHcjtbxrNe0IQ/profile-treasury-document-cover-images_1920/0/1583955040854?e=1692892800&v=beta&t=D3NbkjKbxpReIZKSV2uU8tw1FLMhbIkCcImTytjP6Og'}, {'url': None, 'title': 'SLR in moderate to severe ulcerative colitis', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQF7Onmx0B5S5g/profile-treasury-document-cover-images_1920/0/1583849818805?e=1692892800&v=beta&t=82SCrFE3E9frKJtEAvj5JmUaVPAf8nb5KEclgHuXGOM'}, {'url': None, 'title': 'Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQF92WyV8pGcDA/profile-treasury-document-cover-images_1920/0/1584139412892?e=1692892800&v=beta&t=hj9vrWkHKMVun14mmLsfc8jO2ymbiQ2zkzpk183I3Ag'}, {'url': None, 'title': 'Relative efficacy of bivalirudin vs. heparin monotherapy in STEMI patients treated with primary percutaneous coronary intervention â\x80\x93 a network meta-analysis', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQEkHLjtDwllcQ/profile-treasury-document-cover-images_1920/0/1583743559133?e=1692892800&v=beta&t=61py5it4GlW0R1wMJh0cgTzDnaPkpptFJYtejQlTl3I'}, {'url': None, 'title': 'Relationship between microbiological eradication and clinical outcome with antibiotic treatment in nosocomial pneumonia, complicated urinary tract infection, and complicated intra-abdominal infection', 'description': '', 'image': 'https://media.licdn.com/dms/image/C512DAQFz1yPhrWTwuA/profile-treasury-document-cover-images_1920/0/1584017990424?e=1692892800&v=beta&t=vd1c5w3UCcTzoKf0hc8lp6ggDCDozOuI0rnyfhrE3M0'}]","{'primary_locale': {'country': 'US', 'language': 'en'}, 'supported_locales': [{'country': 'US', 'language': 'en'}], 'profile_languages': [{'name': 'Croatian', 'proficiency': 'NATIVE_OR_BILINGUAL'}, {'name': 'Dutch', 'proficiency': 'PROFESSIONAL_WORKING'}, {'name': 'English', 'proficiency': 'NATIVE_OR_BILINGUAL'}, {'name': 'Serbian', 'proficiency': 'NATIVE_OR_BILINGUAL'}]}",Medical Device,"[{'date': {'start': {'month': 9, 'day': None, 'year': 2016}, 'end': {'month': 11, 'day': None, 'year': 2022}}, 'school': {'name': 'University of Groningen', 'logo': 'https://media.licdn.com/dms/image/C560BAQHjFD1KsBlUnQ/company-logo_400_400/0/1519868080428?e=1700092800&v=beta&t=zwHZthqGYeY_GDI5v0n8SgPTwr4MXQrF9poTgHWrNXU', 'url': 'https://www.linkedin.com/school/rijksuniversiteit-groningen/'}, 'degree_name': 'Doctor of Philosophy (Ph.D.)', 'field_of_study': 'Health Economics'}, {'date': {'start': {'month': None, 'day': None, 'year': 2004}, 'end': {'month': None, 'day': None, 'year': 2005}}, 'school': {'name': 'University of Belgrade', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQGnhcKnnxCu6g/company-logo_400_400/0/1563004770230?e=1700092800&v=beta&t=yp8f2TplKKZOhV8q6TE-VZQ4xYQgsS-StD2nKiKrMxU', 'url': 'https://www.linkedin.com/school/university-of-belgrade/'}, 'degree_name': 'MSc. of Pharmacoeconomy and Pharm.Legislation', 'field_of_study': 'health economics, pharmaceutical legislation'}, {'date': {'start': {'month': None, 'day': None, 'year': 1998}, 'end': {'month': None, 'day': None, 'year': 2004}}, 'school': {'name': 'University of Belgrade', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQGnhcKnnxCu6g/company-logo_400_400/0/1563004770230?e=1700092800&v=beta&t=yp8f2TplKKZOhV8q6TE-VZQ4xYQgsS-StD2nKiKrMxU', 'url': 'https://www.linkedin.com/school/university-of-belgrade/'}, 'degree_name': 'Master of Pharmacy', 'field_of_study': 'pharmacy,pharmacology, health economics'}]",[],[],"[{'name': 'Effective Negotiating Skills', 'date': {'start': {'month': 11, 'day': None, 'year': 2016}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'Rotterdam School of Management, Erasmus University', 'url': None, 'license_number': None, 'display_source': None, 'company': {'id': None, 'name': 'Rotterdam School of Management, Erasmus University', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQGxI95CurHtdA/company-logo_400_400/0/1657183585379?e=1700092800&v=beta&t=wcvw_9EzVh_JYZeGzoSxG1SP51Nx0KA0nxS6Q9eY5Rs', 'url': None}}, {'name': 'Critical Perspectives on Management', 'date': {'start': {'month': 4, 'day': None, 'year': 2016}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'IE Business School', 'url': 'https://www.coursera.org/account/accomplishments/verify/3QW8DU85HNYJ', 'license_number': '3QW8DU85HNYJ', 'display_source': 'coursera.org', 'company': {'id': None, 'name': 'IE Business School', 'logo': 'https://media.licdn.com/dms/image/C4D0BAQGvE_Hi22X6lQ/company-logo_400_400/0/1663153931884?e=1700092800&v=beta&t=QkBidlKuM85DcnUep9kkiJbpBHh34MKjzpL4qZ3FE-U', 'url': None}}, {'name': 'Organizational Analysis (Self-Paced)', 'date': {'start': {'month': 1, 'day': None, 'year': 2015}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'Stanford University', 'url': 'https://www.coursera.org/course/organalysis', 'license_number': None, 'display_source': 'coursera.org', 'company': {'id': None, 'name': 'Stanford University', 'logo': 'https://media.licdn.com/dms/image/C560BAQHr9suxyJBXMw/company-logo_400_400/0/1635534378574?e=1700092800&v=beta&t=0I4xa8TYRextFJG2v-r54-g48NbJwFslIdSKS29IAHM', 'url': None}}, {'name': 'Drug Discovery, Development & Commercialization', 'date': {'start': {'month': 12, 'day': None, 'year': 2014}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'University of California, San Diego. Coursera Verified Certificates', 'url': 'https://www.coursera.org/signature/certificate/962YVLBWHR', 'license_number': '962YVLBWHR', 'display_source': 'coursera.org', 'company': None}, {'name': 'Course: ""Discrete Event Simulation for Economic Analyses – Applications""', 'date': {'start': {'month': 11, 'day': None, 'year': 2014}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'International Society for Pharmacoeconomics and Outcomes Research  (ISPOR)', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'ISPOR Member', 'date': {'start': {'month': 10, 'day': None, 'year': 2014}, 'end': {'month': 10, 'day': None, 'year': 2015}}, 'authority': 'ISPOR', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Programming in Excel with VBA', 'date': {'start': {'month': 2, 'day': None, 'year': 2014}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': ""Compu'Train"", 'url': 'http://www.computrain.nl', 'license_number': None, 'display_source': 'computrain.nl', 'company': {'id': None, 'name': 'Computrain', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQFwGplJ7wijTQ/company-logo_400_400/0/1519856069371?e=1700092800&v=beta&t=KRKD8BTWKkq5laE4QfuKSfM3kTPFc8XDikZ04tcMl-M', 'url': None}}, {'name': 'Case-Based Introduction to Biostatistics', 'date': {'start': {'month': 8, 'day': None, 'year': 2013}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'The Johns Hopkins University', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Interprofessional Healthcare Informatics', 'date': {'start': {'month': 6, 'day': None, 'year': 2013}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'The University of Minnesota - School of Nursing', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Knowledge Assessment Methodology Tool Training Course', 'date': {'start': {'month': 4, 'day': None, 'year': 2013}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'The World Bank Institute', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Online course: Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)', 'date': {'start': {'month': 1, 'day': None, 'year': 2010}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'ISPOR', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Online course: Cost-Minimization (CMA) / Cost Consequence Analysis', 'date': {'start': {'month': 1, 'day': None, 'year': 2010}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'ISPOR', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Online course: Cost-of-Illness / Cost Estimation (COI/CE)', 'date': {'start': {'month': 1, 'day': None, 'year': 2010}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'ISPOR', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Online course: The Role of Pharmacoeconomics', 'date': {'start': {'month': 8, 'day': None, 'year': 2004}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'ISPOR', 'url': None, 'license_number': None, 'display_source': None, 'company': None}, {'name': 'Online course: Corporate Social Responsibility', 'date': {'start': {'month': 4, 'day': None, 'year': 2004}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'The World Bank Institute', 'url': None, 'license_number': None, 'display_source': None, 'company': None}]","[{'name': 'Clinical Medical Reviews and Case reports', 'position': 'Member of the Editorial Board', 'date_start': {'month': 7, 'day': None, 'year': 2014}, 'date_end': None}, {'name': 'Science Journal of Public Health', 'position': 'Member of the Editorial Board', 'date_start': {'month': 4, 'day': None, 'year': 2014}, 'date_end': None}]",[],"[{'name': 'Impact of surgical complications on hospital costs and revenues: Retrospective database study of Medicare claims', 'publisher': 'Journal of Comparative Effectiveness Research', 'url': 'https://becarispublishing.com/doi/10.57264/cer-2023-0080', 'date': {'month': None, 'day': None, 'year': 2023}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Samer', 'last_name': 'Haidar', 'name': None, 'headline': 'Hemodynamics Director at Philips'}]}, {'name': 'Costs and outcomes of mobile cardiac outpatient telemetry monitoring post-transcatheter aortic valve replacement', 'publisher': 'Journal of Comparative Effectiveness Research', 'url': 'https://www.futuremedicine.com/doi/10.2217/cer-2022-0112', 'date': {'month': None, 'day': None, 'year': 2022}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Belinda', 'last_name': 'Acuña Mohr', 'name': None, 'headline': 'Associate Director, Health Economics and Outcomes Research at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Manish', 'last_name': 'Wadhwa', 'name': None, 'headline': 'Chief Medical Officer, Cardiac Electrophysiologist'}, {'type': 'standardizedContributor', 'first_name': 'Jennifer', 'last_name': 'Lavelle', 'name': None, 'headline': 'Head of Global Business Marketing, Ambulatory, Monitoring & Diagnostics at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Daniel', 'last_name': 'Buchenberger, MS', 'name': None, 'headline': '.'}, {'type': 'standardizedContributor', 'first_name': 'Vincent', 'last_name': 'Norlock', 'name': None, 'headline': 'New market development and strategy for healthcare products and services'}]}, {'name': 'Outpatient cardiac telemetry monitoring for early patient discharge: continuous focused rhythm surveillance for patients recovering outside of the hospital setting', 'publisher': 'Journal of Cardiology & Current Research', 'url': None, 'date': {'month': None, 'day': None, 'year': 2022}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Vasily', 'last_name': 'Lukyanov', 'name': None, 'headline': 'Health economics and outcomes research in pharma and medical device industry'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Purvee Parikh', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Heather Luke', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Jennifer', 'last_name': 'Lavelle', 'name': None, 'headline': 'Head of Global Business Marketing, Ambulatory, Monitoring & Diagnostics at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Andrew Armanious', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Leigh Ann Kelly', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Manish', 'last_name': 'Wadhwa', 'name': None, 'headline': 'Chief Medical Officer, Cardiac Electrophysiologist'}]}, {'name': 'Economics of implementing an early deterioration detection solution for general care patients at a US hospital', 'publisher': 'Journal of Comparative Effectiveness Research', 'url': 'https://www.futuremedicine.com/doi/10.2217/cer-2021-0222', 'date': {'month': None, 'day': None, 'year': 2021}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Belinda', 'last_name': 'Acuña Mohr', 'name': None, 'headline': 'Associate Director, Health Economics and Outcomes Research at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Diane Bartos', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Stephen Dickson', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Libby Bucsi', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Mariska Vente', 'headline': None}]}, {'name': 'Evidence-based Clinical Decision Support Systems for the prediction and detection of three disease states in critical care: A systematic literature review', 'publisher': 'F1000 Research', 'url': 'https://f1000research.com/articles/8-1728/v1', 'date': {'month': None, 'day': None, 'year': 2019}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Melodi Kosaner Kließ', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Louis Atallah', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Jochen Weichert', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Saswat', 'last_name': 'P.', 'name': None, 'headline': 'U.S. Market Access at Intuitive'}, {'type': 'standardizedContributor', 'first_name': 'Maarten', 'last_name': 'Postma', 'name': None, 'headline': 'Professor at University of Groningen'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Amer EL-Kerdi', 'headline': None}]}, {'name': 'Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in ', 'publisher': 'Antimicrobial Resistance & Infection Control', 'url': 'https://doi.org/10.1186/s13756-017-0264-2', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Vimalanand', 'last_name': 'Prabhu', 'name': None, 'headline': 'Director - Outcomes Research (Oncology-Endometrial Cancer) at Merck'}, {'type': 'standardizedContributor', 'first_name': 'Teresa', 'last_name': 'Kauf', 'name': None, 'headline': 'Global HEOR and Market Access Leader, Oncology & Rare Disease Expert'}]}, {'name': 'A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis', 'publisher': 'Current Medical Research and Opinion', 'url': 'http://www.tandfonline.com/eprint/Uhr6Jka7DRBuj2rkDP6g/full', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Miriam', 'last_name': 'Rouhof-van der Weijden', 'name': None, 'headline': 'Psycholoog / orthopedagoog bij Praktijk de Engh'}, {'type': 'standardizedContributor', 'first_name': 'Andreas', 'last_name': 'Karabis', 'name': None, 'headline': 'Vice President, Head of Real World Methods & Evidence Generation Team in EMEA at IQVIA'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe', 'publisher': 'ISPOR US poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Katherine', 'last_name': 'Young', 'name': None, 'headline': 'Principal Consultant, Market Access | MD, Health Economist'}, {'type': 'standardizedContributor', 'first_name': 'Mondher', 'last_name': 'Toumi', 'name': None, 'headline': 'Serial successful entrepreneur and recognized academic in Life Sciences! Chief Executive Officer at InovIntell, Professor of Public Health at Aix-Marseille University and President of Market Access Society.'}, {'type': 'standardizedContributor', 'first_name': 'Maarten', 'last_name': 'Postma', 'name': None, 'headline': 'Professor at University of Groningen'}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Short- and long-term health consequences of sleep disruption', 'publisher': 'Nature and Science of Sleep', 'url': 'https://www.dovepress.com/articles.php?article_id=32942', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections', 'publisher': 'BMC Infectious Diseases', 'url': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2408-7', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Teresa Kauf', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Vimalanand', 'last_name': 'Prabhu', 'name': None, 'headline': 'Director - Outcomes Research (Oncology-Endometrial Cancer) at Merck'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Rebekah H. Borse', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Benjamin Miller', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Jennifer', 'last_name': 'Gaultney', 'name': None, 'headline': 'Director in Health Economics and HTA at IQVIA'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Shuvayu S. Sen', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Anirban Basu', 'headline': None}]}, {'name': 'Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe', 'publisher': 'Journal of Market Access & Health Policy', 'url': 'http://www.tandfonline.com/doi/full/10.1080/20016689.2017.1299665', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Daria Korchagina', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Katherine', 'last_name': 'Young', 'name': None, 'headline': 'Principal Consultant, Market Access | MD, Health Economist'}, {'type': 'standardizedContributor', 'first_name': 'Mondher', 'last_name': 'Toumi', 'name': None, 'headline': 'Serial successful entrepreneur and recognized academic in Life Sciences! Chief Executive Officer at InovIntell, Professor of Public Health at Aix-Marseille University and President of Market Access Society.'}, {'type': 'standardizedContributor', 'first_name': 'Maarten', 'last_name': 'Postma', 'name': None, 'headline': 'Professor at University of Groningen'}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Cost-effectiveness of Levofloxacin Inhalation Solution vs. Aztreonam Inhalation Solution in Cystic fibrosis patients in Belgium', 'publisher': 'ISPOR poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Marcel', 'last_name': 'Westen', 'name': None, 'headline': 'Company Owner at Rareconsult.eu b.v.'}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Cost-effectiveness of Levofloxacin Inhalation Solution vs. Aztreonam Inhalation Solution and Tobramycin dry powder for inhalation in Cystic fibrosis patients in Sweden', 'publisher': 'ISPOR poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Karin Franck-Larsson', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Sissel', 'last_name': 'Rodahl', 'name': None, 'headline': 'SVP & Commercial Head GenSight Biologics'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-Analysis', 'publisher': 'Clinical Therapeutics', 'url': 'http://www.clinicaltherapeutics.com/article/S0149-2918(16)30661-0/abstract', 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Stuart Elborn', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Anne-Lise', 'last_name': 'Vataire', 'name': None, 'headline': 'Outcomes Research Manager'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Ayako Fukushima', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Samuel', 'last_name': 'Aballéa', 'name': None, 'headline': 'COO at InovIntell'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Amine Khemiri', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Curtis Moorea', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Delayed release versus immediate release cysteamine for patients with nephropathic cystinosis: Modelled differences in life expectancy and quality of life', 'publisher': 'Poster - Global Halth Economics Summit', 'url': 'http://www.esciencecentral.org/journals/2375-4273/2375-4273.C1.021_003.pdf', 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Micheline', 'last_name': 'Wille', 'name': None, 'headline': 'Vice President Medical Affairs GenSight Biologics'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Azharul Mannan', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Peter Hudson', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Michiel ', 'last_name': 'Hemels ', 'name': None, 'headline': 'Global Biotech Executive '}]}, {'name': 'Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison', 'publisher': 'Advances in Therapy', 'url': 'http://link.springer.com/article/10.1007%2Fs12325-016-0299-4', 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Leandro Lindner', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Miriam', 'last_name': 'Rouhof-van der Weijden', 'name': None, 'headline': 'Psycholoog / orthopedagoog bij Praktijk de Engh'}, {'type': 'standardizedContributor', 'first_name': 'Andreas', 'last_name': 'Karabis', 'name': None, 'headline': 'Vice President, Head of Real World Methods & Evidence Generation Team in EMEA at IQVIA'}]}, {'name': 'Using An Economic Model to Choose Initial Appropriate Antibiotic Therapy Based on Differences in In-vitro Susceptibility to Ceftolozane/Tazobactam and Piperacillin/Tazobactam', 'publisher': 'ISPOR Poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2015}, 'authors': [{'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Vimalanand S. Prabhu', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Shuvayu S. Sen', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Benjamin W. Miller', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Anirban Basu', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}]}, {'name': 'Use of Surveillance Data to Examine the Cost-effectiveness of Alternative Approaches to Empiric Antibiotic Therapy in Gram-negative Nosocomial Pneumonia', 'publisher': 'ATS poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2015}, 'authors': [{'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Teresa L. Kauf', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Matthew Dryden', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Peng', 'last_name': 'Xu', 'name': None, 'headline': 'Business Development, New Product Launch, Pricing & Market Access, Strategic Consulting'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Marya D. Zilberberg', 'headline': None}]}, {'name': 'Systematic Literature Review of Treatments of Chronic Cluster Headache', 'publisher': 'ISPOR poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2015}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Thavaneswaran Shanti', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Papadimitropoulou Katerina', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Stauble Funke', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Andreas', 'last_name': 'Karabis', 'name': None, 'headline': 'Vice President, Head of Real World Methods & Evidence Generation Team in EMEA at IQVIA'}]}, {'name': 'Relationship Between Microbiological Eradication and Clinical Outcome With Antibiotic Treatment in Nosocomial Pneumonia, Complicated Urinary Tract Infection, and Complicated Intra-abdominal Infection', 'publisher': 'ISPOR poster', 'url': None, 'date': {'month': None, 'day': None, 'year': 2014}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Goran', 'last_name': 'Medic, PhD, Pharm.D.', 'name': None, 'headline': 'Director HEOR at Philips'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen Paul', 'last_name': 'Jansen', 'name': None, 'headline': 'Associate Professor, University of California - San Francisco; Chief Scientist - Health Economics & Outcomes Research '}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Teresa Kauf', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Shawn Eapen', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Martin Kollef', 'headline': None}]}]",[],[],"[{'company': {'id': 1090, 'name': 'Philips', 'logo': 'https://media.licdn.com/dms/image/C510BAQG4O5wCG6zf2Q/company-logo_400_400/0/1519855869410?e=1700092800&v=beta&t=lwbs3fZHITA_Bs1N2t36YOUxeHQkcuA8pCYt7ENTexk', 'url': 'https://www.linkedin.com/company/philips/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 10, 'day': None, 'year': 2017}, 'end': {'month': None, 'day': None, 'year': None}}, 'profile_positions': [{'location': 'Eindhoven, North Brabant, Netherlands', 'date': {'start': {'month': 11, 'day': None, 'year': 2020}, 'end': {'month': None, 'day': None, 'year': None}}, 'company': 'Philips', 'description': ""•\tOverseeing the global digital transformation of Philips devices and solutions for improved performance and efficiency\n•\tFormulating and implementing a worldwide HEOR data generation strategy for the Connected Care Business Cluster, ensuring successful launches of Philips products and services\n•\tDirecting the creation of evidence, materials, and scientific publications aimed at economic stakeholders to support market positioning\n•\tManaging the generation of HEOR deliverables essential for clinical development, regulatory engagement, market access, and internal governance milestones\n•\tSpearheading collaborations and communications with external experts (Key Opinion Leaders – KOLs) for evidence generation and scientific data exchange\n•\tShaping R&D efforts by influencing the design of clinical programs to optimize market adoption\n•\tEstablishing a unified, standardized set of HEOR deliverables tailored to the Connected Care Business Cluster\n•\tProviding strategic guidance for acquisition plans and target start-up valuations, such as the Biotelemetry acquisition\n      o\tEnsuring the seamless integration of Biotelemetry into Philips' operations\n•\tCollaborating with the Clinical Development Team to devise and lead HEOR projects that reinforce value propositions in line with the Quadruple Aim"", 'title': 'Director HEOR', 'employment_type': 'Full-time'}, {'location': 'Eindhoven Area, Netherlands', 'date': {'start': {'month': 10, 'day': None, 'year': 2017}, 'end': {'month': 10, 'day': None, 'year': 2020}}, 'company': 'Philips', 'description': ""• Working closely with marketing, sales, and R&D teams to devise and execute health economic and market access strategies for the entire Philips portfolio in Europe, spanning from research phase to product launch\no Integrating suitable health economics and market access (HEMA) tools and methodologies into the I2M (idea to market) processes and stage-gate decision-making\n• Cooperating with the HEMA organization, business groups, and clinical-marketing teams on trial design and protocols to yield scientifically sound outcomes related to economic value\no Guiding the trial design and outcome measurements for Clinical Decision Support Systems\n• Understanding and communicating the implications of emerging payer and government policies to internal teams and clients, which may affect market access possibilities for Philips offerings, while participating in Philips' external dialogue and stakeholder interactions.\no Amending the NICE Guidelines on the treatment pathway of coronary revascularization using instantaneous wave-free ratio\n• Establishing and maintaining productive relationships with key internal and external financial stakeholders to promote product awareness and positively influence market access adoption decisions\n• Steering the development of dossiers and models\n• Creating evidence, materials, and scientific publications for economic stakeholders\n• Providing due diligence input for acquisition strategies and/or valuation of target start-up companies\n     o NightBalance BV acquisition"", 'title': 'Senior Manager HEOR', 'employment_type': 'Full-time'}]}, {'company': {'id': None, 'name': 'Chiesi Group (Former Raptor Pharmaceuticals, Horizon Plc)', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 1, 'day': None, 'year': 2016}, 'end': {'month': 9, 'day': None, 'year': 2017}}, 'profile_positions': [{'location': 'Utrecht Area, Netherlands', 'date': {'start': {'month': 1, 'day': None, 'year': 2016}, 'end': {'month': 9, 'day': None, 'year': 2017}}, 'company': 'Chiesi Group (Former Raptor Pharmaceuticals, Horizon Plc)', 'description': ""•\tRaptor Pharmaceuticals (Jan 2016-Sept 2016) was acquired by Horizon Pharma (Oct 2016 - June 2017), that was later acquired by Chiesi Group.\n•\tStreamlined commercialization of Quinsair® for cystic fibrosis, achieving national reimbursement in multiple countries (Germany, Netherlands, Scotland, Denmark, Sweden, Wales, Ireland, Finland, Norway, Luxemburg). Developed a manuscript to support HTA submissions and negotiated reimbursements with AWMSG. Utilized International Reference Pricing Model and global competitor data to optimize pricing.\n•\tImplemented market access strategy for Quinsair® in markets where national reimbursement wasn't optimal, such as Italy, Austria, and Switzerland. Crafted credible payer and patient value stories for launch markets and led a project on SLR and NMA comparisons for HTA submissions.\n•\tChampioned payer perspective in brand strategy, authored manuscripts supporting claims, and revised pricing and market access strategies for life cycle management. Provided strategic recommendations and financial analyses for named patient programs in some countries.\n•\tManaged KOL relationships alongside Medical Affairs, resulting in successful payer conversions in Saudi Arabia and Kuwait. Coordinated local plans and dossiers in alignment with established forecast and budget timelines."", 'title': 'Market Access Manager Europe', 'employment_type': None}]}, {'company': {'id': 1114612, 'name': 'Mapi Group', 'logo': 'https://media.licdn.com/dms/image/C560BAQELzX3ZI2DE6A/company-logo_400_400/0/1519900787504?e=1700092800&v=beta&t=SDkIa4GoMoTJ6A7lupTGnza6PoEBDal-4ANSjgcdfeI', 'url': 'https://www.linkedin.com/company/mapi-group/', 'employees': {'start': 501, 'end': 1000}}, 'date': {'start': {'month': 1, 'day': None, 'year': 2011}, 'end': {'month': 12, 'day': None, 'year': 2015}}, 'profile_positions': [{'location': 'Utrecht Area, Netherlands', 'date': {'start': {'month': 3, 'day': None, 'year': 2015}, 'end': {'month': 12, 'day': None, 'year': 2015}}, 'company': 'Mapi Group: Health Research & Commercialization', 'description': '• Guiding research teams for effective project delivery and client satisfaction\n• Advancing business development via proposal writing\n• Developing health economic models and reimbursement dossiers (AMCP, IQWiG, NICE, SMC, ZIN)\no\tWrote dossier for ceftolozane/tazobactam for AMCP which led to positive formulary listings in the USA\n• Actively engaging in medical writing (articles/manuscripts) for submission to peer-reviewed journals. \n• Composing HTA value documents to effectively communicate health economic and additional value propositions for enhanced drug/device accessibility.\n• Managing KOLs', 'title': 'Research Consultant', 'employment_type': None}, {'location': 'Utrecht Area, Netherlands', 'date': {'start': {'month': 1, 'day': None, 'year': 2014}, 'end': {'month': 2, 'day': None, 'year': 2015}}, 'company': 'Mapi Group: Health Research & Commercialization', 'description': '• Creating health economic models for reimbursement and global marketing\n• Writing reimbursement submission dossiers (AMCP, IQWiG, NICE, SMC, ZIN)\n• Medical writing (articles/manuscripts) for peer-reviewed journals\n• Conducting (systematic) literature reviews and network meta-analyses\n• Drafting HTA value documents for optimal drug/device access\n• Managing KOLs\n• Driving business development, resulting in repeat client projects', 'title': 'Senior Research Associate', 'employment_type': None}, {'location': 'Utrecht Area, Netherlands', 'date': {'start': {'month': 1, 'day': None, 'year': 2011}, 'end': {'month': 12, 'day': None, 'year': 2013}}, 'company': 'Mapi Group: Health Research & Commercialization', 'description': '• Conducting (systematic) literature reviews and network meta-analyses\n• Creating health economic models for global reimbursement and marketing\n• Communicating value messages effectively\n• Establishing robust HTA value propositions for drug/device access\n• Managing KOLs', 'title': 'Research Associate – HEOR & Strategic Market Access', 'employment_type': None}]}, {'company': {'id': 3862365, 'name': 'KCI Europe Holding B.V.', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQHy7NJzW12-Fg/company-logo_400_400/0/1574791298937?e=1700092800&v=beta&t=RGEWfrBhHROOZALqSuAMYwGeyjkuq1NwTCMwahMcm-E', 'url': 'https://www.linkedin.com/company/acelity/', 'employees': {'start': 1001, 'end': 5000}}, 'date': {'start': {'month': 9, 'day': None, 'year': 2008}, 'end': {'month': 1, 'day': None, 'year': 2011}}, 'profile_positions': [{'location': 'Amsterdam Area, Netherlands', 'date': {'start': {'month': 9, 'day': None, 'year': 2008}, 'end': {'month': 1, 'day': None, 'year': 2011}}, 'company': 'Acelity', 'description': '• Developing Budget Impact Models in Excel and Flash\n• Crafting strong HTA propositions for KCI product access\n• Investigating reimbursement systems and pathways\n• Maintaining Reimbursement Knowledgebase, tools, and materials in collaboration with US/EMEA departments\n• Assisting Senior Director by gathering healthcare data and summarizing reports', 'title': 'Coordinator Health Economics and Reimbursement', 'employment_type': None}]}, {'company': {'id': 100248, 'name': 'Cambridge Cell Networks', 'logo': None, 'url': 'https://www.linkedin.com/company/cambridge-cell-networks/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 8, 'day': None, 'year': 2006}, 'end': {'month': 9, 'day': None, 'year': 2008}}, 'profile_positions': [{'location': 'Novi Sad, Serbia', 'date': {'start': {'month': 8, 'day': None, 'year': 2006}, 'end': {'month': 9, 'day': None, 'year': 2008}}, 'company': 'Cell Networks', 'description': ""• Analyzing molecular drug/chemical mechanisms\n• Exploring disease mechanisms in metabolic disorders, inflammation, and oncology\n• Assessing ToxWiz software's health economics"", 'title': 'Application Scientist', 'employment_type': None}]}, {'company': {'id': 48886, 'name': 'Dymaxium Inc.', 'logo': 'https://media.licdn.com/dms/image/C560BAQH0xcNV-fzPQA/company-logo_400_400/0/1519857006182?e=1700092800&v=beta&t=I0jtWjFKXDqPh6wnMVvKR2yHBDCkTn_fvwOktqHcSos', 'url': 'https://www.linkedin.com/company/dymaxium-inc-/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 8, 'day': None, 'year': 2007}, 'end': {'month': 7, 'day': None, 'year': 2008}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 8, 'day': None, 'year': 2007}, 'end': {'month': 7, 'day': None, 'year': 2008}}, 'company': 'Dymaxium Inc.', 'description': '• Creating customer-centric economic models using real-world data\n• Crafting value presentations, messages, abstracts, and payer slide kits\n• Developing health economics training for internal teams and external stakeholders\n• Supporting HEOR projects under team leaders and client guidance', 'title': 'Research Associate', 'employment_type': None}]}, {'company': {'id': None, 'name': 'Pharmacy Sombor', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 8, 'day': None, 'year': 2004}, 'end': {'month': 8, 'day': None, 'year': 2006}}, 'profile_positions': [{'location': 'Sombor, Serbia', 'date': {'start': {'month': 8, 'day': None, 'year': 2004}, 'end': {'month': 8, 'day': None, 'year': 2006}}, 'company': 'Pharmacy Sombor', 'description': '• Dispensing medicines and providing patient guidance\n• Analyzing data on medication usage, pharmacovigilance and pharmacoeconomic research', 'title': 'Master of Pharmacy, specialist of pharmacoeconomy', 'employment_type': None}]}]",[],"['US market', 'European Markets', 'Real World Evidence (RWE)', 'Literature Reviews', 'Comparative Effectiveness', 'Health Economics', 'Outcomes Research', 'HTA', 'Market Access', 'Pharmacoeconomics', 'Health Outcomes', 'Economic Modeling', 'Medical Devices', 'Pharmaceuticals', 'Healthcare', 'Reimbursement', 'Medical Writing', 'Crystal Xcelsius 2008', 'Microsoft Excel', 'Data Analysis']",,,
